表紙:モノクローナル抗体の世界市場 - 市場シェア、規模、動向、業界分析:ソースタイプ別、生産タイプ別、用途別、エンドユーザー別、地域別、セグメント予測(2022年~2030年)
市場調査レポート
商品コード
1150058

モノクローナル抗体の世界市場 - 市場シェア、規模、動向、業界分析:ソースタイプ別、生産タイプ別、用途別、エンドユーザー別、地域別、セグメント予測(2022年~2030年)

Monoclonal Antibodies Market Share, Size, Trends, Industry Analysis Report, Source Type (Chimeric, Murine, Humanized, Human); By Production Type (In Vivo, In Vitro); By Application; By End-use; By Region; Segment Forecast, 2022 - 2030

出版日: | 発行: Polaris Market Research | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円
モノクローナル抗体の世界市場 - 市場シェア、規模、動向、業界分析:ソースタイプ別、生産タイプ別、用途別、エンドユーザー別、地域別、セグメント予測(2022年~2030年)
出版日: 2022年10月01日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のモノクローナル抗体の市場規模は、2030年までに4,791億3,000万米ドルに達すると予測されています。

当レポートでは、世界のモノクローナル抗体市場について調査分析し、市場力学、セグメント分析、地域分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • レポート説明
    • 調査目的
    • 市場範囲
    • 前提条件
  • ステークホルダー

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • データソース
    • 一次ソース
    • 二次ソース

第4章 世界のモノクローナル抗体市場の洞察

  • モノクローナル抗体:業界のスナップショット
  • モノクローナル抗体市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力(中)
    • 新規参入者の脅威(低)
    • 買い手の交渉力(中)
    • 代替品の脅威(中)
    • 既存企業間の競争力(高)
  • PESTLE分析
  • モノクローナル抗体業界の動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界のモノクローナル抗体市場:ソースタイプ別

  • 主要な調査結果
  • イントロダクション
    • ソースタイプ別:2018年~2030年
  • マウス
    • マウス別、地域別:2018年~2030年
  • キメラ
    • キメラ別、地域別:2018年~2030年
  • ヒト化
    • ヒト化別、地域別:2018年~2030年
  • ヒト
    • ヒト別、地域別:2018年~2030年

第6章 世界のモノクローナル抗体市場:生産タイプ別

  • 主要な調査結果
  • イントロダクション
    • 生産タイプ別:2018年~2030年
  • インビボ
    • インビボ別、地域別:2018年~2030年
  • インビトロ
    • インビトロ別、地域別:2018年~2030年

第7章 世界のモノクローナル抗体市場:用途別

  • 主要な調査結果
  • イントロダクション
    • 用途別:2018年~2030年
  • 腫瘍学
    • 腫瘍学別、地域別:2018年~2030年
  • 自己免疫疾患
    • 自己免疫疾患別、地域別:2018年~2030年
  • 感染症
    • 感染症別、地域別:2018年~2030年
  • 神経疾患
    • 神経疾患別、地域別:2018年~2030年
  • その他
    • その他別、地域別:2018年~2030年

第8章 世界のモノクローナル抗体市場:エンドユーザー別

  • 主要な調査結果
  • イントロダクション
    • エンドユーザー別:2018年~2030年
  • 病院
    • 病院別、地域別:2018年~2030年
  • 専門センター
    • 専門センター別、地域別:2018年~2030年
  • その他
    • その他別、地域別:2018年~2030年

第9章 世界のモノクローナル抗体市場:地域別

  • 主要な調査結果
  • イントロダクション
    • モノクローナル抗体市場評価 - 地域別:2018年~2030年
  • 北米
    • ソースタイプ別:2018年~2030年
    • エンドユーザー別:2018年~2030年
    • 生産タイプ別:2018年~2030年
    • 用途別:2018年~2030年
    • 米国
    • カナダ
  • 欧州
    • ソースタイプ別:2018年~2030年
    • エンドユーザー別:2018年~2030年
    • 生産タイプ別:2018年~2030年
    • 用途別:2018年~2030年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
  • アジア太平洋
    • ソースタイプ別:2018年~2030年
    • エンドユーザー別:2018年~2030年
    • 生産タイプ別:2018年~2030年
    • 用途別:2018年~2030年
    • 中国
    • インド
    • 日本
    • マレーシア
    • インドネシア
    • 韓国
  • 中東・アフリカ
    • ソースタイプ別:2018年~2030年
    • エンドユーザー別:2018年~2030年
    • 生産タイプ別:2018年~2030年
    • 用途別:2018年~2030年
    • サウジアラビア
    • 南アフリカ
    • イスラエル
    • アラブ首長国連邦
  • ラテンアメリカ
    • ソースタイプ別:2018年~2030年
    • エンドユーザー別:2018年~2030年
    • 生産タイプ別:2018年~2030年
    • 用途別:2018年~2030年
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 競合情勢

  • 事業拡張と買収の分析
    • 事業拡張
    • 買収
  • 提携/協業/協定/展示会

第11章 企業プロファイル

  • Abbott Laboratories
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • F. Hoffman-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Novartis
  • Pfizer Inc
  • Sanofi S.A.
  • Thermo Fisher Scientific, Inc.
  • Viatris Inc.
図表

List of Tables

  • Table 1 Global Monoclonal Antibodies Market, by Source Type, by Region, 2018 - 2030 (USD Billion)
  • Table 2 Global Monoclonal Antibodies Market, by Production Type, by Region, 2018 - 2030 (USD Billion)
  • Table 3 Global Monoclonal Antibodies Market, by Application, by Region, 2018 - 2030 (USD Billion)
  • Table 4 Global Monoclonal Antibodies Market, by End-Use, by Region, 2018 - 2030 (USD Billion)
  • Table 5 Monoclonal Antibodies Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 6 North America: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 7 North America: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 8 North America: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 9 North America: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 10 U.S.: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 11 U.S.: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 12 U.S.: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 13 U.S.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 14 Canada: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 15 Canada: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 16 Canada: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 17 Canada: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 18 Europe: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 19 Europe: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 20 Europe: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 21 Europe: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 22 Germany: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 23 Germany: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 24 Germany: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 25 Germany: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 26 France: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 27 France: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 28 France: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 29 France: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 30 UK: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 31 UK: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 32 UK: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 33 UK: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 34 Italy: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 35 Italy: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 36 Italy: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 37 Italy: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 38 Netherlands: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 39 Netherlands: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 40 Netherlands: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 41 Netherlands: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 42 Spain: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 43 Spain: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 44 Spain: Monoclonal Antibodies Market, by Application 2018 - 2030 (USD Billion)
  • Table 45 Spain: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 46 Russia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 47 Russia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 48 Russia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 49 Russia: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 50 Asia Pacific: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 51 Asia Pacific: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 52 Asia Pacific: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 53 Asia Pacific: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 54 China: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 55 China: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 56 China: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 57 China: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 58 Japan: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 59 Japan: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 60 Japan: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 61 Japan: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 62 India: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 63 India: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 64 India: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 65 India: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 66 Indonesia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 67 Indonesia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 68 Indonesia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 69 Indonesia: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 70 Malaysia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 71 Malaysia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 72 Malaysia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 73 Malaysia: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 74 South Korea: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 75 South Korea: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 76 South Korea: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 77 South Korea: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 78 Latin America: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 79 Latin America: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 80 Latin America: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 81 Latin America: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 82 Brazil: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 83 Brazil: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 84 Brazil: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 85 Brazil: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 86 Mexico: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 87 Mexico: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 88 Mexico: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 89 Mexico: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 90 Argentina: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 91 Argentina: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 92 Argentina: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 93 Argentina: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 94 Middle East & Africa: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 95 Middle East & Africa: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 96 Middle East & Africa: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 97 Middle East & Africa: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 98 UAE: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 99 UAE: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 100 UAE: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 101 UAE: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 102 Saudi Arabia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 103 Saudi Arabia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 104 Saudi Arabia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 105 Saudi Arabia: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 106 South Africa: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 107 South Africa: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 108 South Africa: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 109 South Africa: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 110 Israel: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • Table 111 Israel: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • Table 112 Israel: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • Table 113 Israel: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Monoclonal Antibodies Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up End-Use

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Source Type

Figure 7. Global Monoclonal Antibodies Market, by Source Type, 2021 & 2030 (USD Billion)

Figure 8. Market by End-Use

Figure 9. Global Monoclonal Antibodies Market, by End-Use, 2021 & 2030 (USD Billion)

Figure 10. Market by Production Type

Figure 11. Global Monoclonal Antibodies Market, by Production Type, 2021 & 2030 (USD Billion)

Figure 12. Market by Application

Figure 13. Global Monoclonal Antibodies Market, by Product, 2021 & 2030 (USD Billion)

Figure 14. Monoclonal Antibodies Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 15. Strategic Analysis - Monoclonal Antibodies Market

目次
Product Code: PM1104

The global Monoclonal Antibodies market size is expected to reach USD 479.13 billion by 2030, according to a new study by Polaris Market Research. The report "Monoclonal Antibodies Market Share, Size, Trends, Industry Analysis Report, By Source Type (Chimeric, Murine, Humanized, Human), By Production Type (In Vivo, In Vitro), By Application, By End-use, By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides an analysis of future market growth.

The increasing uses of mAb therapies, rising government initiatives in infection control and management, and growing cancer incidences, with the demand for cost-effective biosimilar monoclonal antibodies, are the major factors driving the market. In addition, the high demand for biologics, the expansion of genomics R&D activities, and the introduction of technologically advanced genetic platforms like next-generation sequencing also spur market growth.

Furthermore, the monoclonal antibody market has grown due to the COVID-19 virus outbreak. Effective treatments are required due to the sudden increase in individuals with COVID-19 and the mortality risk associated with the illness. Additionally, due to their potential to reduce disease burden, numerous industry participants are consistently working to create novel mAb for the prevention and treatment of the COVID-19 virus. These antibodies are an efficient alternative for decreasing COVID-19, and the US FDA has given emergency use authorizations (EUA) for several of these antibodies.

Monoclonal Antibodies Market Report Highlights

In 2021, the human source category segment had the most significant proportion. Human monoclonal antibody product approvals and an increase in medicine launches contribute to the segment's growth. The market for this segment is predicted to grow due to human mAb in treating numerous infectious diseases.

The low levels of contamination provided by the method and the availability of improved biomanufacturing capabilities made in vitro production type the dominant type in 2021.

Due to the increasing number of mAb cancer therapies that have received approval, as well as growing public and scientific knowledge of these treatments, the oncology segment held the majority of the market in 2021.

Use of monoclonal antibodies for cancer treatment in hospitals and rising healthcare spending that favors the adoption of such medicines, hospitals made up the highest proportion of the end-use segment in 2021.

North America held the largest market share owing to Increasing Industry R&D spending and government financing for cancer research, which have aided in developing innovative monoclonal antibody treatments.

Major players operating in the industry include Abbott Laboratories, Amgen Inc, AstraZeneca plc, Bayer AG, Biogen Inc., Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc, Sanofi S.A., Thermo Fisher Scientific, Inc.,and Viatris Inc.

Polaris Market Research has segmented the Monoclonal Antibodies Market report based on raw material, type, technology, end-use, and region:

Monoclonal Antibodies, Source type Outlook (Revenue - USD Billion, 2018 - 2030)

Murine

Chimeric

Humanized

Human

Monoclonal Antibodies, Production Type Outlook (Revenue - USD Billion, 2018 - 2030)

In Vivo

In Vitro

Monoclonal Antibodies Application Outlook (Revenue - USD Billion, 2018 - 2030)

Oncology

Autoimmune Diseases

Infectious Diseases

Neurological Diseases

Others

Monoclonal Antibodies, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Specialty Centers

Others

Monoclonal Antibodies, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Monoclonal Antibodies Market Insights

  • 4.1. Monoclonal Antibodies - Industry Snapshot
  • 4.2. Monoclonal Antibodies Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Incidences Of Chronic Diseases
      • 4.2.1.2. Technological Advancements
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost Of Therapeutic Mabs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Monoclonal Antibodies Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Monoclonal Antibodies Market, by Source Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • 5.3. Murine
    • 5.3.1. Global Monoclonal Antibodies Market, by Murine, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Chimeric
    • 5.4.1. Global Monoclonal Antibodies Market, by Chimeric, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Humanized
    • 5.5.1. Global Monoclonal Antibodies Market, by Humanized, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Human
    • 5.6.1. Global Monoclonal Antibodies Market, by Human, by Region, 2018 - 2030 (USD Billion)

6. Global Monoclonal Antibodies Market, by Production Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • 6.3. In Vivo
    • 6.3.1. Global Monoclonal Antibodies Market, by In Vivo, by Region, 2018 - 2030 (USD Billion)
  • 6.4. In Vitro
    • 6.4.1. Global Monoclonal Antibodies Market, by In Vitro, by Region, 2018 - 2030 (USD Billion)

7. Global Monoclonal Antibodies Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 7.3. Oncology
    • 7.3.1. Global Monoclonal Antibodies Market, by Oncology, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Autoimmune Diseases
    • 7.4.1. Global Monoclonal Antibodies Market, by Autoimmune Diseases, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Infectious Diseases
    • 7.5.1. Global Monoclonal Antibodies Market, by Infectious Diseases, by Region, 2018 - 2030 (USD Billion)
  • 7.6. Neurological Diseases
    • 7.6.1. Global Monoclonal Antibodies Market, by Neurological Diseases, by Region, 2018 - 2030 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Monoclonal Antibodies Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Monoclonal Antibodies Market, by End-Use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.3. Hospitals
    • 8.3.1. Global Monoclonal Antibodies Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Speciality Centres
    • 8.4.1. Global Monoclonal Antibodies Market, by Speciality Centres, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Others
    • 8.5.1. Global Monoclonal Antibodies Market, by Others, by Region, 2018 - 2030 (USD Billion)

9. Global Monoclonal Antibodies Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Monoclonal Antibodies Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Monoclonal Antibodies Market - North America
    • 9.3.1. North America: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.3.5. Monoclonal Antibodies Market - U.S.
      • 9.3.5.1. U.S.: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.3.6. Monoclonal Antibodies Market - Canada
      • 9.3.6.1. Canada: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4. Monoclonal Antibodies Market - Europe
    • 9.4.1. Europe: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.5. Monoclonal Antibodies Market - UK
      • 9.4.5.1. UK: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.6. Monoclonal Antibodies Market - France
      • 9.4.6.1. France: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.7. Monoclonal Antibodies Market - Germany
      • 9.4.7.1. Germany: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.8. Monoclonal Antibodies Market - Italy
      • 9.4.8.1. Italy: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.9. Monoclonal Antibodies Market - Spain
      • 9.4.9.1. Spain: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.10. Monoclonal Antibodies Market - Netherlands
      • 9.4.10.1. Netherlands: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.11. Monoclonal Antibodies Market - Russia
      • 9.4.11.1. Russia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5. Monoclonal Antibodies Market - Asia Pacific
    • 9.5.1. Asia Pacific: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.5. Monoclonal Antibodies Market - China
      • 9.5.5.1. China: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.6. Monoclonal Antibodies Market - India
      • 9.5.6.1. India: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.7. Monoclonal Antibodies Market - Japan
      • 9.5.7.1. Japan: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.8. Monoclonal Antibodies Market - Malaysia
      • 9.5.8.1. Malaysia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.9. Monoclonal Antibodies Market - Indonesia
      • 9.5.9.1. Indonesia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.10. Monoclonal Antibodies Market - South Korea
      • 9.5.10.1. South Korea: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.6. Monoclonal Antibodies Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.6.5. Monoclonal Antibodies Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.6.6. Monoclonal Antibodies Market - South Africa
      • 9.6.6.1. South Africa: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.6.7. Monoclonal Antibodies Market - Israel
      • 9.6.7.1. Israel: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.6.8. Monoclonal Antibodies Market - UAE
      • 9.6.8.1. UAE: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.7. Monoclonal Antibodies Market - Latin America
    • 9.7.1. Latin America: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.7.5. Monoclonal Antibodies Market - Mexico
      • 9.7.5.1. Mexico: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.7.6. Monoclonal Antibodies Market - Brazil
      • 9.7.6.1. Brazil: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
    • 9.7.7. Monoclonal Antibodies Market - Argentina
      • 9.7.7.1. Argentina: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbott Laboratories
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Amgen Inc
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. AstraZeneca plc
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bayer AG
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Biogen Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Bristol Myers Squibb
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Daiichi Sankyo Company Limited
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Eli Lilly and Company
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. F. Hoffman-La Roche Ltd.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. GlaxoSmithKline plc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Johnson & Johnson Services, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck & Co., Inc.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Merck KGaA
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novo Nordisk A/S
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Novartis
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Pfizer Inc
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Sanofi S.A.
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Thermo Fisher Scientific, Inc.
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development
  • 11.19. Viatris Inc.
    • 11.19.1. Company Overview
    • 11.19.2. Financial Performance
    • 11.19.3. Product Benchmarking
    • 11.19.4. Recent Development